Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome

Christopher P. Cannon; Steen Husted; Robert A. Harrington; Benjamin M. Scirica; Håkan Emanuelsson; Gary Peters; Robert F. Storey

doi:10.1016/j.jacc.2007.07.053

Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome

著者: Christopher P. Cannon, Steen Husted, Robert A. Harrington, Benjamin M. Scirica, Håkan Emanuelsson, Gary Peters, Robert F. Storey - Journal of the American College of Cardiology 2007 被引用: 495

Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome | Litlas